Orlando, Florida, November 5 (ots/PRNewswire) - Resverlogix Corp.
("Resverlogix") (TSX:RVX) is pleased to announce today key scientific
data was presented in an oral presentation highlighting the novel
features of RVX-208, at the American Heart Association Scientific
Meetings. The presentation titled "Oral Administration of Compound
RVX-208 Increases Serum Levels of ApoA-I and Improves High-Density
Lipoprotein-Mediated Cholesterol Efflux in African Green Monkeys,"
was presented by Dr. Jacques Genest.
Dr. Jacques Genest, MD, Director of the Division of Cardiology at
McGill University Health Centre/Royal Victoria Hospital said, "We
were excited about this data and felt that it should be presented at
this prestigious conference. Resverlogix's novel drug demonstrated
the ability to increase the production of ApoA-I and functional HDL.
Notably we saw increases in pre beta HDL sub particles, which improve
HDL's ability to mediate cholesterol efflux."
"We are very pleased to have our data presented at one of the most
prestigious conferences for cardiovascular disease," stated Dr. Jan
Johansson, MD, Ph.D., Senior Vice President, Clinical Affairs of
Resverlogix. "Our small molecule, RVX-208, by virtue of increasing
endogenous production of ApoA-I and functional HDL has huge potential
to address the unmet medical need of cardiovascular disease," added
Apolipoprotein A-I (ApoA-I), the main component of high-density
lipoprotein (HDL) represent the bodies natural defense system against
atherosclerosis by mediating reverse cholesterol transport, i.e.
transport of peripheral cholesterol including that of the vessel wall
to the liver for processing. In multiple human and animal studies
over-expression or repeated infusion of ApoA-I inhibit progression
and induce regression of atherosclerosis in animals and humans. In
his presentation Dr. Genest discussed the effects of oral
administration of RVX-208 on serum ApoA-I levels, HDL subspecies
distribution and the functional improvements of serum to promote
cellular cholesterol efflux from vulnerable plaque cells. The mere
fact that the data is based on African Green monkeys in a context of
dose-response makes it predictive for similar treatment effects in
About Cardiovascular Disease (CVD)
CVD can be generally defined as any abnormal condition
characterized by dysfunction of the heart and blood vessels. CVD
includes atherosclerosis (especially coronary heart disease which can
lead to heart attacks), cerebrovascular disease (stroke), and
hypertension (high blood pressure). The underlying cause of most CVD
is a gradual clogging of the arteries (atherosclerosis) that supply
blood to the heart, brain and other vital organs.
The American Heart Association estimates that almost 80 million
American Adults have one or more types of cardiovascular disease. CVD
remains the number one killer of developed nations. Nearly 2400
Americans die each day from cardiovascular disease - that is 1 person
will die every 36 seconds.
About Resverlogix Corp.
Resverlogix Corp. is a leading biotechnology company engaged in
the development of novel therapies for important global medical
markets with significant unmet needs. The NexVas(TM) program is the
Company's primary focus which is to develop novel small molecules
that enhance ApoA-I. These vital therapies address the grievous
burden of atherosclerosis and other important diseases such as acute
coronary syndrome, diabetes, Alzheimer's and other vascular
disorders. The Company's secondary focus is TGF-Beta Shield(TM), a
program that aims to address burgeoning grievous diseases, such as
cancer and fibrosis. Resverlogix Corp. trades on the Toronto Stock
Exchange (TSX:RVX). For further information please visit
This news release may contain certain forward-looking statements
that reflect the current views and/or expectations of Resverlogix
Corp. with respect to its performance, business and future events.
Such statements are subject to a number of risks, uncertainties and
assumptions. Actual results and events may vary significantly. The
TSX Exchange does not accept responsibility for the adequacy or
accuracy of this news release.
ots Originaltext: Resverlogix Corp.
Im Internet recherchierbar: http://www.presseportal.ch
For further information please contact: Theresa Kennedy, VP,
Corporate Communications, Resverlogix Corp., Phone: +1-604-538-7072,
Fax: +1-403-256-8495, Email: Theresa@resverlogix.com; Sarah
Zapotichny, Manager, Investor Relations, Resverlogix Corp., Phone:
+1-403-254-9252, Fax: +1-403-256-8495, Email: Sarah@resverlogix.com